Cargando…

The Rise and Fall of Anticoagulation with Bivalirudin During Percutaneous Coronary Interventions: A Review Article

Bivalirudin is a direct thrombin inhibitor used during percutaneous coronary intervention (PCI). Treatment with bivalirudin compared to heparin plus glycoprotein IIb/IIIa inhibitors (GPI) reduced bleeding complications, but resulted in higher rates of ischemic events, including acute stent thrombosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andreou, Constantinos, Maniotis, Christos, Koutouzis, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446815/ https://www.ncbi.nlm.nih.gov/pubmed/28105561 http://dx.doi.org/10.1007/s40119-017-0082-x

Ejemplares similares

Bivalirudin in percutaneous coronary intervention
por: Lehman, Sam J, et al.
Publicado: (2006)

Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin
por: Ramana, Ravi K, et al.
Publicado: (2008)

Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients
por: Chai, Lina, et al.
Publicado: (2023)

Impact of Diabetes Mellitus on One-Year Clinical Outcomes in Patients Anticoagulated with Bivalirudin Undergoing Elective Percutaneous Coronary Intervention
por: Li, Yulong, et al.
Publicado: (2022)

Bivalirudin Versus Heparin During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
por: Patel, Hiten, et al.
Publicado: (2019)

The effect of bivalirudin and closure device on bleeding outcomes after percutaneous coronary interventions
por: Dobies, David R, et al.
Publicado: (2014)

Is it time to switch to bivalirudin for ECMO anticoagulation?
por: Navaei, Amir, et al.
Publicado: (2023)

Fall and Rise of Coronary Intervention
por: Lahoud, Rony, et al.
Publicado: (2020)

Balloon-assisted tracking for challenging transradial percutaneous coronary intervention
por: Agelaki, Maria, et al.
Publicado: (2017)

Selection of an Aptamer Antidote to the Anticoagulant Drug Bivalirudin
por: Martin, Jennifer A., et al.
Publicado: (2013)

Safety and Effectiveness of Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
por: Ahmad Hamdi, Abdul Hafeez, et al.
Publicado: (2017)

Occurrence and Risk Factors of Adverse Drug Reactions in Patients Receiving Bivalirudin as Anticoagulant During Percutaneous Coronary Intervention: A Prospective, Multi-Center, Intensive Monitoring Study
por: Li, Ping, et al.
Publicado: (2022)

Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials
por: Bavry, Anthony A., et al.
Publicado: (2015)

Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes
por: Farag, Mohamed, et al.
Publicado: (2015)

Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis
por: Li, Jiabei, et al.
Publicado: (2015)

Safety profile of bivalirudin in Chinese female patients undergoing percutaneous coronary intervention: a multi-center study
por: Wu, Fan, et al.
Publicado: (2022)

Bivalirudin for Maintenance Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation for COVID-19
por: Seelhammer, Troy G., et al.
Publicado: (2021)

Primary bivalirudin anticoagulation for patients with an implantable ventricular assist device
por: Pieri, M, et al.
Publicado: (2014)

Efficacy and safety of bivalirudin application during primary percutaneous coronary intervention in older patients with acute ST-segment elevation myocardial infarction
por: Chen, Hongwu, et al.
Publicado: (2020)

Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
por: Li, Senjie, et al.
Publicado: (2021)

A meta‐analysis and cost‐minimization analysis of bivalirudin versus heparin in high‐risk patients for percutaneous coronary intervention
por: Sun, Ke‐Xin, et al.
Publicado: (2021)

Efficacy and safety of bivalirudin without post-procedure infusion in patients with coronary heart disease during elective percutaneous coronary intervention: a real-world study
por: Wang, Ping, et al.
Publicado: (2022)

Periprocedural anticoagulation in transcatheter aortic valve replacement: Heparin vs bivalirudin
por: Minhas, Abdul Mannan Khan, et al.
Publicado: (2017)

Effects of Bivalirudin and Unfractionated Heparin on Liver and Renal Function in Chinese Patients with Coronary Artery Disease Undergoing Coronary Angiography with/without Percutaneous Coronary Intervention
por: Jia, Qiaowei, et al.
Publicado: (2021)

Transulnar sheathless percutaneous coronary intervention during bivalirudin infusion in high-risk elderly female with non-ST segment elevation myocardial infarction
por: Summaria, Francesco, et al.
Publicado: (2012)

Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials
por: Bhogal, Sukhdeep, et al.
Publicado: (2020)

Undilatable Stent Neoatherosclerosis Treated with Ad Hoc Rotational Atherectomy
por: Koutouzis, Michael, et al.
Publicado: (2017)

Heparin Versus Bivalirudin in Acute Myocardial Infarction: Unfractionated Heparin Monotherapy Elevated to Primary Treatment in Contemporary Percutaneous Coronary Intervention
por: Centurión, Osmar Antonio
Publicado: (2016)

Efficacy and safety of bivalirudin vs heparin in patients with coronary heart disease undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
por: Liu, Xiao-Qiang, et al.
Publicado: (2020)

Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation
por: Ranucci, Marco, et al.
Publicado: (2011)

Bivalirudin or heparin: which anticoagulation strategy for critically ill cardiac surgery patients?
por: Pappalardo, F, et al.
Publicado: (2014)

Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support
por: Trigonis, Russell, et al.
Publicado: (2022)

Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: A real world retrospective study
por: Hu, Yue-cheng, et al.
Publicado: (2021)

Bivalirudin vs heparin in cardiac-cerebral ischemic and bleeding events among Chinese STEMI patients during percutaneous coronary intervention: a retrospective cohort study
por: Bai, Zhichao, et al.
Publicado: (2023)

Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society
por: Kołtowski, Łukasz, et al.
Publicado: (2019)

The rise and fall of tobacco smoking and associated rise and fall of coronary atherosclerosis the lethal role of tobacco
por: Lawson, James S.
Publicado: (2023)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Bivalirudin plus loading dose of cilostazol-based triple-antiplatelet in treatment of non-ST-elevation myocardial infarction following percutaneous coronary intervention
por: Wang, Mei, et al.
Publicado: (2015)

Efficacy and safety of bivalirudin versus heparin in patients with diabetes mellitus undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
por: Zhang, Juan, et al.
Publicado: (2017)

Bivalirudin vs. Heparin on Radial Artery Thrombosis during Transradial Coronary Intervention: An Optical Coherence Tomography Study
por: Liu, Zijing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_157f5cpl3k08pqm6gnv7ic4sag